Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban ... in the production of this manuscript. Atrial fibrillation (AF) is the most common cardiac ...

whether Afib patients with a low risk of stroke -- a group without an existing indication for anticoagulation -- were assigned lower-dose rivaroxaban (Xarelto) or placebo (7% vs 6.4%, HR 1.10 ...

Younger patients with the common heart rhythm disorder atrial fibrillation but no other risk ... (JNJ.N), opens new tab under the brand name Xarelto. The others received a placebo.

CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) diagnosis, does nothing to reduce their risk of neurocognitive decline, stroke, ...

A recent study published in JAMA has raised concerns about the safety of certain blood pressure medications for patients with ...